2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Solid Tumor Spine Metastases
1
Sarcoma
1
Rectal Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Lymphoma, Follicular
1
Locally Advanced Colon Cancer
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Astrocytoma
1
Anxiety Disorders
1
Amenorrhea
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
13
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
dodecyl maltoside
5
Radiotherapy
5
Cystoscopy
5
apaziquone
4
ALT-803
4
tislelizumab
3
5-aminolevulinic acid hexyl ester
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
Administration, Intravesical
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
Postoperative Period
×
Clear all
NCT02075060
2017-04-06
IPOI vs IPOP
Poitiers University Hospital
Phase 2
Unknown
54 enrolled